Clinical Trial Update: Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is ongoing to evaluate LY01610 in patients with relapsed small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• LY01610

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Relapsed Small Cell Lung Cancer | Phase 3 | Status: RECRUITING